Landscapes / Companies
ADC Therapeutics S.A. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
1
in active trials · 5 in all
Trials
2 active
17 since 2021
Drugs1
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Approved | Aug 2028Phase 1/2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Aug 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma and 4 more | ||||
| Open drug page | |||||
About
- No active trial
- ADCT-502, ADCT-601, ADCT-901, Camidanlumab Tesirine
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021